Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tenax Therapeutics, Inc.NASDAQ: TENX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $11.54M rose 103.0% year over year, behind the +145.2% change in trailing-twelve-month research & development. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +82.5% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +103.0% toward the trailing-twelve-month pace of +145.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 32.67M USD
- Year-over-year change
- +157.1%
- 4-year CAGR
- +6.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.67M | +157.1% |
| FY2024 | 2024-12-31 | 12.71M | +293.6% |
| FY2023 | 2023-12-31 | 3.23M | -40.0% |
| FY2022 | 2022-12-31 | 5.38M | -78.6% |
| FY2021 | 2021-12-31 | 25.15M | — |
Research & Development vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 research & development of $38.53M is the 4th highest of the 7 companies compared; the peer median is $33.13M.
- Its year-over-year change of +145.2% is the 2nd highest of 7, against a peer median of -3.9%.
- Over three fiscal years its annual growth of +82.5% compares with a peer median of -7.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Jun 2026 | $49.22M | +63.5% | -1.9% | — | |
| LTM Mar 2026 | $42.44M | -21.4% | +6.5% | — | |
| LTM Mar 2026 | $38.53M | +145.2% | +82.5% | — | |
| LTM Mar 2026 | $23.82M | -28.9% | -5.7% | — | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
| LTM Mar 2026 | $10.43M | +13.7% | -10.1% | 28.1% | |
| Peer median (excluding TENX) | $33.13M | -3.9% | -7.9% | 28.2% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.15M | 5.38M | 3.23M | 12.71M | 32.67M |
| Selling, General & Admin | 7.58M | 5.68M | 5.01M | 6.79M | 23.71M |
| Operating Expenses | 32.73M | 11.05M | 8.23M | 19.49M | 56.39M |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| EBITDA | (32.36M) | (10.93M) | (7.68M) | (17.58M) | (52.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.73M) | (11.05M) | (8.23M) | (19.49M) | (56.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 1.91M | 3.82M |
| Interest Expense | 949 | 4.44K | 23.97K | 23K | 0 |
| Other Income / Expenses | 253.88K | 4.75K | 523K | 1.89M | 3.79M |
| Income Before Tax | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2,524.80) | (600.80) | (31.09) | (1.15) | (1.34) |
| EPS (Diluted) | (2,524.80) | (600.80) | (31.04) | (1.15) | (1.34) |
| Weighted Avg Shares | 12.86K | 18.39K | 248K | 15.27M | 39.22M |
| Weighted Avg Shares (Diluted) | 12.86K | 18.39K | 248.45K | 15.27M | 39.22M |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.